October 24, 2022
Read in 2 minutes
Source/Disclosure
The issuer:
Cangemi A, et al. Abstract S514: Virtual reality improves symptoms of functional dyspepsia: results of a randomized, controlled, double-blind pilot study. Presentation: ACG Annual Scientific Conference. October 21-26, 2022. Charlotte, NC (hybrid conference).
Disclosure:
Kanjemi does not report related financial disclosures.
CHARLOTTE, NC — Virtual reality has significantly improved symptoms and quality of life for a small subset of patients with functional dyspepsia, presenters said at the ACG annual science conference.
“Functional dyspepsia, as defined by the ROME IV criteria, is a very common disorder of gut-brain interaction affecting approximately 10% of the population worldwide. … Functional dyspepsia Despite its prevalence, there are currently no FDA-approved treatment options.” David Kanjemi, M.D. Mayo Clinic Jacksonville gastroenterologist said: “Virtual reality is a highly promising intervention that has received a lot of attention in recent years. It has been shown to effectively reduce acute and chronic pain in a variety of clinical settings.”
“In short, we think VR is an interesting new treatment option for functional dyspepsia.” David Kanjemi, M.D. A gastroenterologist at the Mayo Clinic Jacksonville told ACG’s annual scientific conference:
Source: Adobe Stock
In the first randomized, controlled, double-blind pilot study evaluating virtual reality (VR) for the treatment of functional dyspepsia, Cangemi and colleagues studied 37 patients with functional dyspepsia (mean age 45 years). , 81.1% of women) to study the safety and efficacy of VR as a new treatment. A patient in the experimental group (n = 27) received her VR headset with an immersive audiovisual program and a patient in the control group (n = 10) received her identical headset with 2-D nature videos. received.
Participants used the headset at least daily (mean 1.3 times per day, 23.2 minutes per day) at baseline, 1 week, and at the end of the 2-week study.
The study results showed that the total PAGI-SYM score for all patients decreased from 2.51 to 0.62 and the mean total PAGI-SYM score for the experimental group decreased compared to the control group (2.51 to 1.83; mean difference = -0.68). Much improved. 2.04; mean difference = –0.46).
Additionally, the NDI quality of life score increased overall from 40.97 to 57.14, with significant improvement in the experimental and control groups (42 to 60.05 vs. 38.19 to 49.28). Non-serious side effects occurred in her 40.7% and 60% of patients, respectively, but did not result in study completion.
“Virtual reality provided significant overall improvements in symptoms and quality of life in patients with functional dyspepsia,” concluded Cangemi. significantly improved symptom scores and quality of life numerically.”
“In short, we believe that VR is an interesting new treatment option for functional dyspepsia. Clearly, larger, longer-term trials are needed to explore the true benefits of virtual reality, and we intends to be part of that movement moving forward.”
Comments
Post a Comment